Bottom line
FHLC vs RXL: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and RXL (ProShares Ultra Health Care) share a meaningful slice of their top holdings — about 78% by weight.
But FHLC is far broader, holding 337 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.
FHLC is cheaper at 0.084% vs 0.95% — a difference of $87 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +7.2% for FHLC (reporting dates differ).
Updated Nov 19, 2026
FHLC vs RXL side by side
| FHLC | RXL | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Fidelity | ProShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.95% |
| Annual cost per $10k | $8.4 | $95 |
| 10-yr cost on $10k (prospectus) | $108 | $1,305 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +2.6% | +19.7% |
| 5-yr return (annualized) | +7.2% | +7.2% |
| 10-yr return (annualized) | +8.8% | +12.6% |
| Best quarter | +16.4% | +29.7% |
| Worst quarter | −13.1% | −28.9% |
| Net assets (fund) | $3.3B | $72.1M |
| Number of holdings | 337 | 70 |
| Portfolio turnover | 3% | 4% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | RXL | Difference |
|---|---|---|---|
| 2024 | +2.6% | −2.7% | +5.3% |
| 2023 | +2.5% | −3.2% | +5.7% |
| 2022 | −5.5% | −15.1% | +9.7% |
| 2021 | +20.4% | +47.8% | −27.5% |
| 2020 | +18.1% | +19.2% | −1.1% |
| 2019 | +21.9% | +38.9% | −17.0% |
| 2018 | +5.5% | +5.4% | +0.1% |
| 2017 | +23.3% | +46.0% | −22.7% |
| 2016 | −3.3% | −8.9% | +5.6% |
Source: Fund prospectus bar charts
Holdings overlap
21 of FHLC's top 25 holdings also appear in RXL's top 25.
| Holding | FHLC | RXL |
|---|---|---|
| Eli Lilly & Co | 13.35% | 12.67% |
| Johnson & Johnson | 8.93% | 7.86% |
| AbbVie Inc | 6.42% | 5.57% |
| UnitedHealth Group Inc | 5.44% | 4.98% |
| Merck & Co Inc | 4.66% | 4.26% |
| Thermo Fisher Scientific Inc | 3.09% | 2.68% |
| Amgen Inc | 3.00% | 2.62% |
| Abbott Laboratories | 2.66% | 2.15% |
| Gilead Sciences Inc | 2.34% | 2.41% |
| Pfizer Inc | 2.06% | 2.15% |
| Bristol-Myers Squibb Co | 1.93% | 1.68% |
| CVS Health Corp | 1.92% | 1.67% |
| Intuitive Surgical Inc | 1.82% | 2.18% |
| Danaher Corp | 1.80% | 1.66% |
| Vertex Pharmaceuticals Inc | 1.76% | 1.64% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
FAQ
What is the difference between FHLC and RXL?
Which is cheaper, FHLC or RXL?
Should I own both FHLC and RXL?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.